Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Refractory or Relapsed Disease
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Motexafin gadolinium (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 04 Mar 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 17 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Sep 2005 New trial record.